Ogeda SA: Euroscreen announces name change to Ogeda and completion of Series B financing
(Thomson Reuters ONE) -
Euroscreen announces name change to Ogeda and completion of Series B financing
New identity reflects Ogeda's successful transition to GPCR drug discovery &
development
October 19, 2016, 7 a.m. CET - Euroscreen today became Ogeda. The new corporate
identity, as Ogeda, reflects the Company's primary focus on the discovery and
development of first-in-class small molecule drug candidates targeting G-Protein
Coupled Receptors (GPCRs). Ogeda also launched a new corporate website that is
accessible on: www.ogeda.com
The launch of its new corporate brand follows the successful completion of the
second and final tranche of the Company's EUR 18 million Series B financing,
which was first announced in October 2015. The second tranche of funding was
subject to the completion of clinical milestones with lead product ESN364, which
is currently in three parallel Phase IIa trials for Menopausal Hot Flashes,
PolyCystic Ovary Syndrome (PCOS) and Uterine Fibroids. All milestones were
achieved ahead of schedule and the additional funds will be used to fully
finance the ongoing clinical programs.
Jean Combalbert, CEO of Ogeda, said: "Our new identity reflects our ambition to
continue to explore new frontiers in the discovery and development of medicines
based on our long-established expertise in GPCRs. With the successful completion
of the Series B funding round and our lead clinical trial program for ESN364 on
track, we look forward to continued progress in inventing and developing
innovative treatments in areas of significant unmet need."
Ogeda's services unit Euroscreen Fast, offering an integrated services solution
for GPCR R&D projects, will continue to operate under its current name as a
business unit of Ogeda.
About Ogeda
Ogeda is a Belgium-based, privately owned Drug Discovery Company developing
first-in-class small molecule drug candidates targeting G-Protein Coupled
Receptors (GPCRs). The Company's orally-available and highly specific lead
product ESN364 is currently in Phase II clinical development for the treatment
of Women's Health Disorders. Ogeda has additional small molecules targeting
GPCRs in preclinical development in multiple therapeutic areas including CNS,
endocrinology and inflammation. Ogeda is backed by leading investors, including
Vesalius Biocapital, Fund+ and SRIW. For more information, please
visit: www.ogeda.com
About ESN364
ESN364 is a proprietary, oral, small-molecule, discovered and developed by Ogeda
for the purpose of the treatment of Women's Health Disorders. ESN364 is superior
to the existing, marketed GnRH ligands as it reduces levels of the ovarian
hormones estrogen and progesterone in a non-castrating manner as required for
the safe, effective treatment of UF and Endometriosis. In addition, its
selective action on gonadotropins uniquely positions ESN364 for the treatment of
PCOS. Furthermore, its mechanism of action to mimic the neuronal effects of
estrogen to control body temperature supports the use of ESN364 to directly and
safely address the basis for Hot Flashes in menopausal women.
Contacts
Ruth Devenyns Jean Combalbert
Chief Financial Officer Chief Executive Officer
+32 71 348 500 +32 71 348 520
info(at)ogeda.com info(at)ogeda.com
Consilium Strategic Communications
Chris Gardner, Jonathan Birt, Hendrik Thys and Melissa
Gardiner
+44 20 3709 5700
ogeda(at)consilium-comms.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ogeda SA via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 21.10.2016 - 12:12 Uhr
Sprache: Deutsch
News-ID 502086
Anzahl Zeichen: 4464
contact information:
Town:
Gosselies
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 211 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ogeda SA: Euroscreen announces name change to Ogeda and completion of Series B financing"
steht unter der journalistisch-redaktionellen Verantwortung von
Ogeda SA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
